Synlogic announces appointment of michael jensen as chief financial officer

Cambridge, mass., march 03, 2022 (globe newswire) -- synlogic, inc. (nasdaq: sybx), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of michael jensen as chief financial officer. mr. jensen brings extensive and diversified experience within global pharmaceutical and medical device companies to synlogic, spanning analytics, financial management, information systems, and operations.
SYBX Ratings Summary
SYBX Quant Ranking